乐普生物宣布,其EGFR ADC MRG003联合PD-1单抗获欧洲药品管理局批准,启动局晚期头颈鳞癌II期临床试验,为全球首个该领域临床研究。该研究有望重塑治疗格局,提升患者生存期与生活质量。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.